701-1188

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2013-02-15

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Mild APPLICATION SITE URTICARIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-21 (study day 35.0); relationship: PROBABLE

mild assessed

Mild ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-16 (study day 2.0); relationship: PROBABLE

moderate assessed

Moderate ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-16 (study day 2.0); relationship: PROBABLE

mild assessed

Mild PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-16 (study day 2.0); relationship: PROBABLE

moderate assessed

Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-16 (study day 2.0); relationship: PROBABLE

mild assessed

Mild URTICARIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-04 (study day 18.0); relationship: PROBABLE

moderate assessed

Moderate URTICARIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-04 (study day 18.0); relationship: PROBABLE

mild assessed

Mild URTICARIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-21 (study day 35.0); relationship: PROBABLE

Data queries

No data queries.